持续脑池内尼莫地平给药作为动脉瘤性蛛网膜下腔出血难治性血管痉挛的挽救治疗
6个月时93.3%患者mRS≤1(中位mRS 1,范围1-4),但53%出现新发痉挛相关神经功能缺损需追加动脉内尼莫地平,13%发生术后急性硬膜下/硬膜外血肿,13%发生导管意外移位需再手术。持续脑池内尼莫地平可能是难治性痉挛的可行挽救治疗,但治疗相关并发症风险增加。
要点
- 经眶上开颅置管持续脑池内尼莫地平可用于难治性脑血管痉挛的挽救治疗
- 6个月功能独立比例高(93.3% mRS≤1),但需注意选择偏倚
- 治疗相关并发症包括新发神经缺损、术后血肿和导管移位
核心结论
- 持续脑池内尼莫地平给药可能是难治性脑血管痉挛的可行挽救治疗选择,但治疗相关并发症风险增加。
主要发现
- 6个月mRS≤1者占93.3%(中位mRS 1,范围1-4)。
- 8例(53%)在鞘内尼莫地平治疗期间出现新发脑血管痉挛相关神经功能缺损,并额外接受动脉内尼莫地平团注。
- 2例(13%)术后发生急性硬膜下/硬膜外血肿,其中1例接受手术治疗。
- 2例(13%)发生鞘内导管意外移位,需再次手术。
临床怎么用
- 对于经诱导高血压和血管内血管扩张治疗仍难治的症状性脑血管痉挛患者,可考虑持续脑池内尼莫地平作为挽救治疗。
- 治疗期间需警惕新发神经功能缺损、术后血肿和导管移位等并发症。
局限性
- 单中心回顾性观察性研究,样本量仅15例,无对照组,结论需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Delayed cerebral ischaemia (DCI) and cerebral vasospasm (CVS) remain major causes of poor outcome in survivors of aneurysmal subarachnoid haemorrhage (aSAH). We aimed to investigate the safety and efficacy of intracisternal administration of nimodipine in patients suffering from symptomatic CVS refractory to treatment with induced hypertension and endovascular vasodilator therapy. METHODS: We performed a single-centre, retrospective, observational study including all patients diagnosed with refractory CVS after aSAH treated at our tertiary centre between January 2018 and December 2021 who received continuous intracisternal nimodipine. For nimodipine administration, a catheter was inserted in the optico-carotid cistern via supraorbital craniotomy. Our primary outcome was functional independence measured by the modified Rankin Scale (mRS) at 6 months. Secondary outcomes included treatment related complications and neurological outcome. RESULTS: We included 15 patients in total. Clinical outcome measured by the mRS at 6 months was good with 93.3% of patients showing mRS ≤ 1 (median mRS 1; range 1-4) Eight patients (53%) developed a new CVS-related neurological deficit during intrathecal nimodipine treatment and additionally received bolus intra-arterial nimodipine. Two patients (13%) developed acute subdural/epidural hematoma postoperatively, which was treated surgically in one patient. In two patients (13%), accidental dislocation of the intrathecal catheter occurred, which warranted re-operation. CONCLUSION: Continuous intracisternal administration of nimodipine may be a viable rescue therapy option for patients with refractory CVS but is associated with an increased risk of treatment related complications.
引用
- Müller MD, Janosovits K, Bervini D, et al. Continuous intracisternal nimodipine administration as rescue therapy for refractory vasospasm in patients with aneurysmal subarachnoid haemorrhage. Acta Neurochir (Wien). 2025. PMID: 41186788. doi:10.1007/s00701-025-06702-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。